Clover Biopharmaceuticals-B Surges Over 6% on Positive Phase II Data for Respiratory Combination Vaccine in Australia

Stock News

Yesterday

Shares of Clover Bio-B (02197) climbed more than 6% during the afternoon trading session. As of the latest update, the stock was up 5.24% to HK$2.01, with trading volume reaching HK$5.486 million.

The recent surge comes as the company unveiled encouraging preliminary results from its Phase II clinical trial in Australia, evaluating its respiratory combination vaccine candidates, SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), among elderly participants.

Additionally, Clover Bio-B has successfully completed the commercial-scale production scale-up of the antigen components for SCB-1022/1033 using a 2000L bioreactor system, along with multiple production batches. Chief Executive Officer Liang Guo highlighted that these favorable trial outcomes considerably mitigate the risks associated with future late-stage development, while also validating the company's differentiated Trimer-Tag platform's capability in creating multivalent protein-based respiratory vaccines.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/news/1100521924"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1100521924\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1100521924?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-14 14:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100521924","market":"sh","top_or_hot":-1,"title":"Clover Biopharmaceuticals-B Surges Over 6% on Positive Phase II Data for Respiratory Combination Vaccine in Australia","media":"Stock News","content":"<p>Shares of <b>Clover Bio-B (02197)</b> climbed more than 6% during the afternoon trading session. As of the latest update, the stock was up 5.24% to HK$2.01, with trading volume reaching HK$5.486 million.<br><br>The recent surge comes as the company unveiled encouraging preliminary results from its Phase II clinical trial in Australia, evaluating its respiratory combination vaccine candidates, SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), among elderly participants.<br><br>Additionally, <b>Clover Bio-B</b> has successfully completed the commercial-scale production scale-up of the antigen components for SCB-1022/1033 using a 2000L bioreactor system, along with multiple production batches. Chief Executive Officer Liang Guo highlighted that these favorable trial outcomes considerably mitigate the risks associated with future late-stage development, while also validating the company's differentiated Trimer-Tag platform's capability in creating multivalent protein-based respiratory vaccines.<br><br></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover Biopharmaceuticals-B Surges Over 6% on Positive Phase II Data for Respiratory Combination Vaccine in Australia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover Biopharmaceuticals-B Surges Over 6% on Positive Phase II Data for Respiratory Combination Vaccine in Australia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-14 14:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>Clover Bio-B (02197)</b> climbed more than 6% during the afternoon trading session. As of the latest update, the stock was up 5.24% to HK$2.01, with trading volume reaching HK$5.486 million.<br><br>The recent surge comes as the company unveiled encouraging preliminary results from its Phase II clinical trial in Australia, evaluating its respiratory combination vaccine candidates, SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), among elderly participants.<br><br>Additionally, <b>Clover Bio-B</b> has successfully completed the commercial-scale production scale-up of the antigen components for SCB-1022/1033 using a 2000L bioreactor system, along with multiple production batches. Chief Executive Officer Liang Guo highlighted that these favorable trial outcomes considerably mitigate the risks associated with future late-stage development, while also validating the company's differentiated Trimer-Tag platform's capability in creating multivalent protein-based respiratory vaccines.<br><br></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KCAI","symbol_name":"KraneShares China Alpha Index ETF","start_time":0,"source_url":"","article_id":"1100521924","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100521924","pubTimestamp":1789369093,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of Clover Bio-B (02197) climbed more than 6% during the afternoon trading session. As of the latest update, the stock was up 5.24% to HK$2.01, with trading volume reaching HK$5.486 million.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KCAI":"KraneShares China Alpha Index ETF","BK4588":"碎股","BK4585":"ETF&股票定投概念","02197":"三叶草生物-B","BK1161":"生物科技","VXUS":"国际股票ETF-Vanguard"},"translate_title":"澳大利亚呼吸道联合疫苗 II 期数据积极，Clover Biopharmaceuticals-B 股价飙升超过 6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02197":1,"KCAI":1,"VXUS":1},"content_text":"Shares of Clover Bio-B (02197) climbed more than 6% during the afternoon trading session. As of the latest update, the stock was up 5.24% to HK$2.01, with trading volume reaching HK$5.486 million.The recent surge comes as the company unveiled encouraging preliminary results from its Phase II clinical trial in Australia, evaluating its respiratory combination vaccine candidates, SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), among elderly participants.Additionally, Clover Bio-B has successfully completed the commercial-scale production scale-up of the antigen components for SCB-1022/1033 using a 2000L bioreactor system, along with multiple production batches. Chief Executive Officer Liang Guo highlighted that these favorable trial outcomes considerably mitigate the risks associated with future late-stage development, while also validating the company's differentiated Trimer-Tag platform's capability in creating multivalent protein-based respiratory vaccines.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}